IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. and Encourages Investors to Contact the Firm

Core Viewpoint - A class action lawsuit has been filed against ImmunityBio, Inc. for allegedly making false and misleading statements regarding its product Anktiva, leading to investor losses during the specified class period from January 19, 2026, to March 24, 2026 [2][3]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Central District of California on behalf of all individuals and entities who purchased ImmunityBio securities during the class period [2]. - Investors have until May 26, 2026, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Allegations - The lawsuit alleges that Patrick Soon-Shiong, a defendant, materially overstated the capabilities of Anktiva, resulting in false and misleading statements about ImmunityBio's business and prospects [3]. - The claims suggest that when the true information became public, investors suffered damages due to the misleading nature of the defendants' statements [3]. Group 3: Next Steps for Investors - Investors who purchased ImmunityBio shares and experienced losses are encouraged to contact the law firm for more information regarding their rights and potential claims [4]. - The law firm offers assistance without any cost or obligation to the investors [4]. Group 4: About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with a focus on representing individual and institutional investors in various types of litigation, including securities and commercial cases [5]. - The firm operates nationwide and has offices in New York, South Carolina, and California [5].